Генетические и молекулярные механизмы устойчивости к болезни Альцгеймера

Болезнь Альцгеймера является наиболее распространённой формой нейродегенеративной деменции, характеризующейся накоплением β-амилоида, гиперфосфорилированного тау-белка и выраженной глиальной реакцией. Несмотря на интенсивное изучение патогенеза заболевания, эффективные патогенетические методы терапии остаются ограниченными. В последние годы особый интерес вызывают редкие генетические варианты, ассоциированные с естественной устойчивостью к болезни Альцгеймера. Наиболее изученными среди них являются варианты APOE3 Christchurch и RELN-COLBOS, обнаруженные у носителей мутации PSEN1 Glu280Ala в колумбийских семьях с аутосомно-доминантной формой заболевания. У этих пациентов когнитивное снижение было отсрочено более чем на два десятилетия по сравнению с типичными случаями, что указывает на наличие эндогенных механизмов нейропротекции. Обзор обобщает современные данные о роли вариантов APOE и RELN в регуляции сигнального каскада Reelin–ApoE, включающего белки DAB1, AKT и GSK3β, участвующие в контроле фосфорилирования тау и синаптической пластичности. Обсуждаются возможные механизмы влияния этих генетических факторов на активность микроглии, астроцитов и сохранение синаптических структур. Понимание молекулярных основ устойчивости мозга к болезни Альцгеймера открывает перспективы для разработки новых патогенетических стратегий, направленных на модуляцию Reelin–ApoE-зависимых путей и профилактику нейродегенерации.

1. Кичерова О.А., Рейхерт Л.И. Болезнь Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018; 118(1): 77-81. https://doi.org/10.17116/jnevro20181181177-81

2. Шевцова К.В., Рожков Д.О., Гришина Д.А., и др. Биологические маркеры болезни Альцгеймера в цереброспинальной жидкости: клинико-лабораторные сопоставления. Неврология, нейропсихиатрия, психосоматика. 2024;16(3):96-102. https://doi.org/10.14412/2074-2711-2024-3-96-102

3. McAleese K.E., Colloby S.J., Thomas A.J., et al. Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. Alzheimers Dement. 2021;17(7):1121-1133. doi: 10.1002/alz.12291.

4. Ferrari C., Sorbi S. The complexity of Alzheimer’s disease: an evolving puzzle. Physiol Rev. 2021;101(3):1047-1081. doi: 10.1152/physrev.00015.2020.

5. Murray M.E., Graff-Radford N.R., Ross O.A., et al. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785-96. doi: 10.1016/S1474-4422(11)70156-9.

6. Thal D.R., Attems J., Ewers M. Spreading of amyloid, tau, and microvascular pathology in Alzheimer’s disease: findings from neuropathological and neuroimaging studies. J Alzheimers Dis. 2014;42 Suppl 4:S421-9. doi: 10.3233/JAD-141461.

7. Bejanin A., Schonhaut D.R., La Joie R., et al.. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain. 2017 Dec 1;140(12):3286-3300. doi: 10.1093/brain/awx243.

8. Arboleda-Velasquez J.F., Lopera F., O’Hare M., et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680-1683. doi: 10.1038/s41591-019-0611-3.

9. Lopera F., Marino C., Chandrahas A.S., et al. Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man. Nat Med. 2023;29(5):1243-1252. doi: 10.1038/s41591-023-02318-3.

10. Sepulveda-Falla D., Sanchez J.S., Almeida M.C., et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia. Acta Neuropathol. 2022;144(3):589-601. doi: 10.1007/s00401-022-02467-8

11. Sepulveda-Falla D. Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature. Mol Neurodegener. 2023;18(1):36. doi: 10.1186/s13024-023-00626-3.

12. Oh J., Eser R.A., Ehrenberg A.J., et al. Profound degeneration of wake-promoting neurons in Alzheimer’s disease. Alzheimers Dement. 2019;15(10):1253-1263. doi: 10.1016/j.jalz.2019.06.3916.

13. Алисейчик М.П., Андреева Т.В., Рогаев Е.И. Иммуногенетические факторы нейродегенеративных заболеваний: роль HLA II класса. Биохимия. 2018;83(9):1385-1398. https://doi.org/10.1134/S0320972518090129

14. Рогаев Е.И. Различные пути нейродегенерации. Биохимия. 2018;83(9):1269-1271. https://doi.org/10.1134/S0320972518090014

15. Пономарева Н.В., Андреева Т.В., Протасова М.А., и др. Генетическая ассоциация гена предрасположенности к болезни Альцгеймера PICALM с показателями когнитивных слуховых вызванных потенциалов при старении. Биохимия. 2018;83(9):1351- 1360. https://doi.org/10.1134/S0320972518090099

16. Ferguson C.M., Hildebrand S., Godinho B.M.D.C., et al. Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer’s disease. Alzheimer’s & Dementia. 2024;20(4):2632-2652. https://doi.org/10.1002/alz.13703

17. Брызгалов Д.В., Кузнецова И.Л., Рогаев Е.И. Усиление и восстановление декларативной памяти: от генетической инженерии до неинвазивных вмешательств. Биохимия. 2018;83(9):1407- 1424. https://doi.org/10.1134/S0320972518090142

18. Schwartzentruber J., Cooper S., Liu J.Z., et al. Genome-wide metaanalysis, fine-mapping and integrative prioritization implicate new Alzheimer’s disease risk genes. Nat Genet. 2021;53(3):392-402. doi: 10.1038/s41588-020-00776-w.

19. Dumitrescu L., Mahoney E.R., Mukherjee S., et al. Genetic variants and functional pathways associated with resilience to Alzheimer’s disease. Brain. 2020;143(8):2561-2575. doi: 10.1093/brain/awaa209.

20. Bellenguez C., Küçükali F., Jansen I.E., et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022; 54(4):412-436. doi: 10.1038/s41588-022-01024-z.

21. Hou J., Hess J.L., Armstrong N., et al. Polygenic resilience scores capture protective genetic effects for Alzheimer’s disease. Transl Psychiatry. 2022;12(1):296. doi: 10.1038/s41398-022-02055-0.

22. Choi S.W., Mak T.S., O’Reilly P.F. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15(9):2759-2772. doi: 10.1038/s41596-020-0353-1

23. Hess J.L., Tylee D.S., Mattheisen M. et al. A polygenic resilience score moderates the genetic risk for schizophrenia. Mol Psychiatry. 2021;26(3):800-815. doi: 10.1038/s41380-019-0463-8.

24. Seto M., Weiner R.L., Dumitrescu L., Hohman T.J. Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions. Mol Neurodegener. 2021;16(1):29. doi: 10.1186/ s13024-021-00452-5 25. Raulin A.C., Doss S.V., Trottier Z.A., et al. ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022;17(1):72. doi: 10.1186/s13024-022-00574-4.

25. Singh P.P., Singh M., Mastana S.S. APOE distribution in world populations with new data from India and the UK. Ann Hum Biol. 2006; 33(3):279-308. doi: 10.1080/03014460600594513.

26. Abondio P., Sazzini M., Garagnani P., et al. The Genetic Variability of APOE in Different Human Populations and Its Implications for Longevity. Genes (Basel). 2019;10(3):222. doi: 10.3390/genes10030222.

27. Belloy M.E., Andrews S.J., Le Guen Y., et al. APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry. JAMA Neurol. 2023;80(12):1284-1294. doi: 10.1001/jamaneurol.2023.3599.

28. Reiman E.M., Arboleda-Velasquez J.F., Quiroz Y.T., et al. Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11(1):667. doi: 10.1038/s41467-019-14279-8.

29. Husain M.A., Laurent B., Plourde M. APOE and Alzheimer’s Disease: From Lipid Transport to Physiopathology and Therapeutics. Front Neurosci. 2021;15:630502. doi: 10.3389/fnins.2021.630502.

30. Jackson R.J., Keiser M.S., Meltzer J.C., et al. APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease. Mol Ther. 2024;32(5):1373-1386. doi: 10.1016/j.ymthe.2024.03.024

31. Liu C.C., Murray M.E., Li X., et al. APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Sci Transl Med. 2021;13(613):eabc9375. doi: 10.1126/scitranslmed.abc9375

32. Le Guen Y., Belloy M.E., Grenier-Boley B., et al. Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurol. 2022;79(7):652-663. doi: 10.1001/jamaneurol.2022.1166.

33. Chemparathy A., Le Guen Y., Chen S., et al. APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s disease pathology. Neuron. 2024 Apr 3;112(7):1110- 1116.e5. doi: 10.1016/j.neuron.2024.01.008.

34. Litvinchuk A., Huynh T.V., Shi Y., et al. Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model. Ann Neurol. 2021;89(5):952-966. doi: 10.1002/ana.26043.

35. Sassi C., Nalls M.A., Ridge P.G., et al. ABCA7 p.G215S as potential protective factor for Alzheimer’s disease. Neurobiol Aging. 2016;46:235.e1-9. doi: 10.1016/j.neurobiolaging.2016.04.004.

36. Li Z., Farias F.H.G., Dube U., Del-Aguila J.L., et al. The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol. 2020;139(1):45-61. doi: 10.1007/s00401-019-02066-0.

37. Jun G., Ibrahim-Verbaas C.A., Vronskaya M., et al. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry. 2016 Jan;21(1):108-17. doi: 10.1038/mp.2015.23.

38. Shi Q., Gutierrez R.A., Bhat M.A. Microglia, Trem2, and Neurodegeneration. Neuroscientist. 2025;31(2):159-176. doi: 10.1177/10738584241254118.

39. Li Y., Xu H., Wang H., et al. TREM2: Potential therapeutic targeting of microglia for Alzheimer’s disease. Biomed Pharmacother. 2023;165:115218. doi: 10.1016/j.biopha.2023.115218.

40. Zhou Y., Ulland T.K., Colonna M. TREM2-Dependent Effects on Microglia in Alzheimer’s Disease. Front Aging Neurosci. 2018;10:202. doi: 10.3389/fnagi.2018.00202.

41. Schlepckow K., Morenas-Rodríguez E., Hong S., Haass C. Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer’s disease. Lancet Neurol. 2023;22(11):1048-1060. doi: 10.1016/S1474-4422(23)00247-8.

42. van Lengerich B., Zhan L., Xia D., et al. A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models. Nat Neurosci. 2023;26(3):416-429. doi: 10.1038/s41593-022-01240-0.

43. Butler C.A., Mendoza Arvilla A., Milinkeviciute G., et al. The Abca7V1613M variant reduces Aβ generation, plaque load, and neuronal damage. Alzheimers Dement. 2024;20(7):4914-4934. doi: 10.1002/alz.13783.

44. Steinberg S., Stefansson H., Jonsson T., et al. Loss-of-function variants in ABCA7 confer risk of Alzheimer’s disease. Nat Genet. 201;47(5):445-7. doi: 10.1038/ng.3246.

45. De Roeck A., Van Broeckhoven C., Sleegers K. The role of ABCA7 in Alzheimer’s disease: evidence from genomics, transcriptomics and methylomics. Acta Neuropathol. 2019;138(2):201-220. doi: 10.1007/s00401-019-01994-1

46. Gialama V., Siokas V., Liampas I., et al. Alzheimer’s Disease and Effects of ABCA7 Polymorphisms: A Review. J Integr Neurosci. 2024;23(9):164. doi: 10.31083/j.jin2309164.

47. Petit D., Fernández S.G., Zoltowska K.M., et al. Aβ profiles generated by Alzheimer’s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Mol Psychiatry. 2022;27(6):2821-2832. doi: 10.1038/s41380-022-01518-6.

48. Jonsson T., Atwal J.K., Steinberg S., et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2012;488(7409):96-9. doi: 10.1038/nature11283

49. Célestine M., Jacquier-Sarlin M., Borel E., et al. Transmissible longterm neuroprotective and pro-cognitive effects of 1-42 beta-amyloid with A2T icelandic mutation in an Alzheimer’s disease mouse model. Mol Psychiatry. 2024;29(12):3707-3721. doi: 10.1038/s41380-024-02611-8.

50. Ando K., Nagaraj S., Küçükali F., et al. PICALM and Alzheimer’s Disease: An Update and Perspectives. Cells. 2022;11(24):3994. doi: 10.3390/cells11243994.

51. Masri I., Salami A., El Shamieh S., Bissar-Tadmouri N. rs3851179G>A in PICALM is Protective Against Alzheimer’s Disease in Five Different Countries Surrounding the Mediterranean. Curr Aging Sci. 2020;13(2):162-168. doi: 10.2174/1874609812666191019143237.

52. Harold D., Abraham R., Hollingworth P., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1088-93. doi: 10.1038/ng.440.

53. Allen M., Zou F., Chai H.S., et al. Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology. 2012;79(3):221-8. doi: 10.1212/WNL.0b013e3182605801.

54. Ma J., Qiu S. Genetic variant rs11136000 upregulates clusterin expression and reduces Alzheimer’s disease risk. Front Neurosci. 2022;16:926830. doi: 10.3389/fnins.2022.926830.

55. Balcar V.J., Zeman T., Janout V., et al. Single Nucleotide Polymorphism rs11136000 of CLU Gene (Clusterin, ApoJ) and the Risk of Late-Onset Alzheimer’s Disease in a Central European Population. Neurochem Res. 2021;46(2):411-422. doi: 10.1007/ s11064-020-03176-y.

56. Tsai A.P., Dong C., Lin P.B., et al. PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer’s disease. Genome Med. 2022;14(1):17. doi: 10.1186/s13073-022-01022-0

57. Magno L., Lessard C.B., Martins M., et al. Alzheimer’s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimers Res Ther. 2019;11(1):16. doi: 10.1186/s13195-019-0469-0.

58. Kleineidam L., Chouraki V., Próchnicki T., et al. PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathol. 2020;139(6):1025-1044. doi: 10.1007/s00401-020-02138-6.

59. Benitez B.A., Jin S.C., Guerreiro R., et al. Missense variant in TREML2 protects against Alzheimer’s disease. Neurobiol Aging. 2014;35(6):1510.e19-26. doi: 10.1016/j.neurobiolaging.2013.12.010.

60. Li J.Q., Zhong X.L., Song J.H., et al. Associations Between TREML2 Gene Variants and Alzheimer’s Disease: Biomarkers, Neuroimage, and Cognition. J Alzheimers Dis. 2023;96(4):1555-1563. doi: 10.3233/JAD-230936.

61. Wang S.Y., Gong P.Y., Yan E., et al. The Role of TREML2 in Alzheimer’s Disease. J Alzheimers Dis. 2020;76(3):799-806. doi: 10.3233/JAD-200406.

62. Bhattarai P., Gunasekaran T.I., Belloy M.E., et al. Rare genetic variation in fibronectin 1 (FN1) protects against APOEε4 in Alzheimer’s disease. Acta Neuropathol. 2024;147(1):70. doi: 10.1007/s00401-024-02721-1.

63. Almeida M.C., Eger S.J., He C., et al. Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer’s disease profile and possible mechanisms of disease protection. Neuron. 2024;112(11):1778-1794.e7. doi: 10.1016/j.neuron.2024.02.009

64. Henao-Restrepo J., López-Murillo C., Valderrama-Carmona P., et al. Gliovascular alterations in sporadic and familial Alzheimer’s disease: APOE3 Christchurch homozygote glioprotection. Brain Pathol. 2023;33(2):e13119. doi: 10.1111/bpa.13119.

65. Quiroz Y.T., Aguillon D., Aguirre-Acevedo D.C., et al. APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease. N Engl J Med. 2024;390(23):2156-2164. doi: 10.1056/NEJMoa2308583.

66. Hernandez I., Gelpi E., Molina-Porcel L., et al. Heterozygous APOE Christchurch in familial Alzheimer’s disease without mutations in other Mendelian genes. Neuropathol Appl Neurobiol. 2021;47(4):579-582. doi: 10.1111/nan.12670.

67. Mah D., Zhu Y., Su G., et al. Apolipoprotein E Recognizes Alzheimer’s Disease Associated 3-O Sulfation of Heparan Sulfate. Angew Chem Int Ed Engl. 2023;62(23):e202212636. doi: 10.1002/anie.202212636

68. Chen Y., Song S., Parhizkar S., et al. APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread. Cell. 2024;187(2):428-445.e20. doi: 10.1016/j.cell.2023.11.029.

69. Nelson M.R., Liu P., Agrawal A., et al. The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. Nat Neurosci. 2023;26(12):2104-2121. doi: 10.1038/s41593-023-01480-8.

70. Perez-Corredor P., Vanderleest T.E., Vacano G.N., et al. APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cellderived cerebral organoids from Alzheimer’s cases. Front Mol Neurosci. 2024;17:1373568. doi: 10.3389/fnmol.2024.1373568.

71. Marino C., Perez-Corredor P., O’Hare M., et al. APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Alzheimers Dement. 2024;20(2):819-836. doi: 10.1002/alz.13436.

72. Chen Y., Holtzman D.M. New insights into innate immunity in Alzheimer’s disease: from APOE protective variants to therapies. Trends Immunol. 2024;45(10):768-782. doi: 10.1016/j.it.2024.08.001

73. Jossin Y. Reelin Functions, Mechanisms of Action and Signaling Pathways During Brain Development and Maturation. Biomolecules. 2020;10(6):964. doi: 10.3390/biom10060964.

74. Katsuyama Y., Hattori M. REELIN ameliorates Alzheimer’s disease, but how? Neurosci Res. 2024;208:8-14. doi: 10.1016/j.neures.2024.07.004.

75. Marckx A.T., Fritschle K.E., Calvier L., Herz J. Reelin changes hippocampal learning in aging and Alzheimer’s disease. Behav Brain Res. 2021;414:113482. doi: 10.1016/j.bbr.2021.113482

76. Lane-Donovan C., Philips G.T., Wasser C.R., et al. Reelin protects against amyloid β toxicity in vivo. Sci Signal. 2015;8(384):ra67. doi: 10.1126/scisignal.aaa6674.

77. Mathys H., Boix C.A., Akay L.A., et al. Single-cell multiregion dissection of Alzheimer’s disease. Nature. 2024;632(8026):858-868. doi: 10.1038/s41586-024-07606-7.

78. Kobro-Flatmoen A., Battistin C., Nair R.R., et al.. Lowering levels of reelin in entorhinal cortex layer II-neurons results in lowered levels of intracellular amyloid-β. Brain Commun. 2023;5(2):fcad115. doi: 10.1093/braincomms/fcad115.

79. Joly-Amado A., Kulkarni N., Nash K.R. Reelin Signaling in Neurodevelopmental Disorders and Neurodegenerative Diseases. Brain Sci. 2023;13(10):1479. doi: 10.3390/brainsci13101479

80. Rossi D., Gruart A., Contreras-Murillo G., et al. Reelin reverts biochemical, physiological and cognitive alterations in mouse models of Tauopathy. Prog Neurobiol. 2020;186:101743. doi: 10.1016/j.pneurobio.2019.101743.

81. Lopez-Font I., Lennol M.P., Iborra-Lazaro G., et al. Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer’s Disease Patients. Int J Mol Sci. 2022;23(14):7522. doi: 10.3390/ijms23147522.

82. Llibre-Guerra J.J., Fernandez M.V., Joseph-Mathurin N., et al.Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia. Nat Med. 2025;31(4):1267-1275. doi: 10.1038/s41591-025-03494-0.

83. Guo Q., Ping L., Dammer E.B., et al. Heparin-enriched plasma proteome is significantly altered in Alzheimer’s disease. Mol Neurodegener. 2024 Oct 8;19(1):67. doi: 10.1186/s13024-024-00757-1.

84. Yi L.X., Zeng L., Wang Q., et al. Reelin links Apolipoprotein E4, Tau, and Amyloid-β in Alzheimer’s disease. Ageing Res Rev. 2024;98:102339. doi: 10.1016/j.arr.2024.102339.

85. Weeber E.J., Beffert U., Jones C., et al. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem. 2002;277(42):39944-52. doi: 10.1074/jbc.M205147200.

86. Ramsden C.E., Zamora D., Horowitz M.S., et al. ApoER2-Dab1 disruption as the origin of pTau-associated neurodegeneration in sporadic Alzheimer’s disease. Acta Neuropathol Commun. 2023;11(1):197. doi: 10.1186/s40478-023-01693-9.

87. Chen G., Wang M., Zhang Z., et al. ApoE3 R136S binds to Tau and blocks its propagation, suppressing neurodegeneration in mice with Alzheimer’s disease. Neuron. 2025;113(5):719-736.e5. doi: 10.1016/j.neuron.2024.12.015. 89. Leng K., Li E., Eser R., et al. Molecular characterization of selectively vulnerable neurons in Alzheimer’s disease. Nat Neurosci. 2021;24(2):276-287. doi: 10.1038/s41593-020-00764-7.

88. Wang N., Wang M., Jeevaratnam S., et al. Opposing effects of apoE2 and apoE4 on microglial activation and lipid metabolism in response to demyelination. Mol Neurodegener. 2022;17(1):75. doi: 10.1186/ s13024-022-00577-1.

89. Fitz N.F., Nam K.N., Wolfe C.M., et al. Phospholipids of APOE lipoproteins activate microglia in an isoform-specific manner in preclinical models of Alzheimer’s disease. Nat Commun. 2021;12(1):3416. doi: 10.1038/s41467-021-23762-0.

90. Lanjakornsiripan D., Pior B.J., Kawaguchi D., et al. Layer-specific morphological and molecular differences in neocortical astrocytes and their dependence on neuronal layers. Nat Commun. 2018;9(1):1623. doi: 10.1038/s41467-018-03940-3

91. Rahimi-Balaei M., Jiao X., Dalvand A., et al. Mutations in the Reelin pathway are associated with abnormal expression of microglial IgG FC receptors in the cerebellar cortex. Mol Biol Rep. 2020;47(7):5323- 5331. doi: 10.1007/s11033-020-05614-0.

92. Guptarak J., Scaduto P., Tumurbaatar B., et al. Cognitive integrity in Non-Demented Individuals with Alzheimer’s Neuropathology is associated with preservation and remodeling of dendritic spines. Alzheimers Dement. 2024;20(7):4677-4691. doi: 10.1002/alz.13900.

93. Singh A., Allen D., Fracassi A., et al. Functional Integrity of Synapses in the Central Nervous System of Cognitively Intact Individuals with High Alzheimer’s Disease Neuropathology Is Associated with Absence of Synaptic Tau Oligomers. J Alzheimers Dis. 2020;78(4):1661-1678. doi: 10.3233/JAD-200716.

94. Fracassi A., Marcatti M., Tumurbaatar B., et al. TREM2-induced activation of microglia contributes to synaptic integrity in cognitively intact aged individuals with Alzheimer’s neuropathology. Brain Pathol. 2023;33(1):e13108. doi: 10.1111/bpa.13108.